Menstrual Cramps Treatment Market Research, 2031
The global menstrual cramps treatment market size was valued at $560.9 million in 2021 and is projected to reach $841.6 million by 2031, growing at a CAGR of 4.1% from 2022 to 2031. Menstrual cramps are pains that occur in lower abdomen and in the back. This is also called dysmenorrhea. This pain may continue for 2 to 3 days. Prostaglandins are chemicals produced by the body that is responsible for many of the symptoms connected with menstrual discomfort. People with high amounts of prostaglandin may experience more acute uterine contractions and pain.
Dysmenorrhea is classified on the basis of type including primary dysmenorrhea and secondary dysmenorrhea. The menstrual cramps treatment is used to relieve menstrual pain. The treatment includes non-steroidal anti-inflammatory drugs and hormonal therapy such as ibuprofen, and naproxen sodium are used to control the pain of cramps. For instance, as per the study published in August 2019 titled "The Prevalence and Academic Impact of Dysmenorrhea in 21,573 Young Women: A Systematic Review and Meta-Analysis", around 71.1% of women had dysmenorrhea in the U.S. 71.1%. Thus, the high prevalence of dysmenorrhea increases the demand for menstrual cramps treatment.
Increase in demand for menstrual cramps treatment due to rise in cases of menstrual cramps drive the menstrual cramps treatment market growth. In addition, increase in government support for healthcare infrastructure improvements further boost the growth of the market. Moreover, low cost of over-the-counter medicines such as ibuprofen leads to increase in demand for menstrual cramps drugs and further drive the market growth. However, side effects of menstrual cramps treatment and poor demand for menstrual cramps treatment in under developed countries may hamper the growth of menstrual cramps treatment market. For instance, side effects of ibuprofen include constipation, diarrhea, heartburn, nervousness, vomiting, and trouble sleeping. In contrast, growth opportunities in emerging market and rise in healthcare expenditure will provide the menstrual cramps treatment market opportunity for market growth.
Impact of COVID-19
The outbreak of COVID-19 has disrupted workflows in the health care sector across the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of health care. However, there has been a negative effect on menstrual cramps treatment industry due to decline in sales of menstrual cramps drugs due to the lockdown. Changes in menstrual cycles cause more dysmenorrhea episodes, which has a substantial impact on the market. For instance, according to National Library Medicine (NIH) study titled "The Impact of the COVID-19 Pandemic on Women’s Reproductive Health", published in March 2021, around 46% of women were reported a change in their menstrual cycle, with 30% women had new dysmenorrhea cases. Thus, COVID-19 had impacted the menstrual cramps treatment industry significantly.
MENSTRUAL CRAMPS TREATMENT MARKET SEGMENTATION
The menstrual cramps treatment market size is segmented into type, treatment type, distribution channel, and region. By type, the market is categorized into primary dysmenorrhea and secondary dysmenorrhea. By treatment type, it is bifurcated into Non-steroidal Anti-inflammatory Drugs (NSAIDs) and hormonal therapy. By distribution channel, it is classified into hospital pharmacies, drug stores & retail pharmacies and online providers. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Segment Review
Depending on type, the market is segmented into primary dysmenorrhea and secondary dysmenorrhea. The primary dysmenorrhea segment was dominated the global market in 2021 and is remain dominant during the menstrual cramps treatment market forecast. The factor which drives the growth of this segment include, rise in incidences of high menstrual bleeding and change in lifestyle, this leads to primary dysmenorrhea.
On the basis of treatment, the market is bifurcated into non-steroidal anti-inflammatory drugs (NSAIDs) and hormonal therapy. The non-steroidal anti-inflammatory drugs (NSAIDs) segment was dominated the market in terms of menstrual cramps treatment market share in 2021 and is the fastest growing segment during the forecast period, owing to advantages of NSAID drugs such as wide availability in pharmacy and drug stores, low cost, and high therapeutic effect.
On the basis of end user, the market is segmented into hospital pharmacies, drug stores & retail stores and online providers. The drug stores & retail pharmacies was dominated the market in terms of revenue in 2021. This was attributed to increased sales of medicines from drug stores & retail pharmacies and increased in patients seeking treatment for menstrual cramps.
On the other hand online providers segment is the fastest revenue contributor to the market. This is attributed to increase in number of smartphone users and higher internet penetration to buy the medicines. For instance, according to report of Global System for Mobile Communications (GSMC), a global organization unifying the mobile ecosystem, in 2021, there were estimated 5.3 billion unique mobile phone users in which 4.2 billion population have active mobile phone internet connection. Furthermore, innovative marketing strategies, introduction of new business models and upsurge in the pharmacies & wellness stores has been anticipated to propel growth of segment.
Region wise, North America acquired a major menstrual cramps treatment market share, owing to the presence of key players, rise in government initiatives. In addition, well-developed healthcare infrastructure in this region further drive the market growth. However, Asia-Pacific is expected to witness the highest growth rate for the menstrual cramps treatment market throughout the forecast period with a highest CAGR.
The factors that drive the growth of the menstrual cramps treatment market in this region is the increase in prevalence of speech disorders. In addition, technological advancements, and increase in government initiatives to promote healthy lifestyle are driving the market growth. Moreover rise in number of hospitals and centers for menstrual cramps treatment in this region further boost the market growth.
The key market players profiled in the report include are Abbott Laboratories, AbbVie Inc., Bayer AG, Dr. Reddy's Laboratories Ltd, GlaxoSmithKline plc, Johnson & Johnson, Pfizer Inc., Sun Pharmaceutical Industries Ltd.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the menstrual cramps treatment market analysis from 2021 to 2031 to identify the prevailing menstrual cramps treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the menstrual cramps treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global menstrual cramps treatment market trends, key players, market segments, application areas, and market growth strategies.
Menstrual Cramps Treatment Market Report Highlights
| Aspects | Details |
 Market Size By 2031 | USD 841.6 million |
 Growth Rate | CAGR of 4.1% |
 Forecast period | 2021 - 2031 |
 Report Pages | 207 |
 By Type |
|
 By Treatment |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Johnson and Johnson, Torrent Pharmaceuticals Ltd., Bayer AG, Abbott Laboratories, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Taj Pharmaceuticals Limited, Pfizer Inc., Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc |
Analyst Review
The global menstrual cramps treatment market is expected to exhibit high growth potential attributable to factors such as rise in in R&D activities in pharmaceutical industry for manufacturing the menstrual cramps drug and surge in number of advancements in the diagnosis and treatment for dysmenorrhea.
Menstrual cramps treatment are used for to reduce the pain and cramps occur during menstrual period. Rise in prevalence of dysmenorrhea, increase in popularity of drug therapy, and surge in awareness regarding menstrual cramps treatment significantly boost the growth of the market. In addition, easy availability of drugs and unhealthy lifestyle can further support the market growth.
Furthermore, North America is expected to witness highest growth, in terms of revenue, owing to higher adoption of menstrual cramps treatment products, increased number of target population, presence of advanced healthcare facilities, easy availability of drugs, and higher health awareness among the general population drives the market growth. In addition, Asia-Pacific is expected to offer lucrative growth opportunities for the key market players during the forecast period, owing to rise in number of menstrual cramps affected population and awareness related to menstrual cramps treatment.
The total market value of menstrual cramps treatmentmarket is $560.8 million in 2021.
The market value of menstrual cramps treatment market in 2031 is $841.57 million
The base year is 2021 in menstrual cramps treatment market.
The forecast period for menstrual cramps treatment market is 2022 to 2031
Primary dysmenorrhea segment is the most influencing segment in menstrual cramps treatmnet market which is attributed to rise in prevalence of primary dysmenorrhea due to rise in depression and anxiety in women.
The major factor that fuels the growth of the menstrual cramps treatment market are rise in cases of menstrual pain in women and growing awareness of menstrual cramps treatment.
Top companies such as AbbVie Inc., Bayer AG, Dr. Reddy’s Laboratories Ltd., and Pfizer Inc. held a high market position in 2021. These key players held a high market postion owing to the strong geographical foothold in different regions.
Asia-Pacific has the highest growth rate in the market with highest CAGR of 4.8%. This is due to increase in health awareness among women and rise in number of hospitals equipped with advanced medical facilities.
Loading Table Of Content...
